Brian Lian - 13 Apr 2023 Form 4 Insider Report for Viking Therapeutics, Inc. (VKTX)

Role: President & CEO, Director
Signature: /s/ Michael Morneau, as Attorney-in-Fact
Issuer symbol: VKTX
Transactions as of: 13 Apr 2023
Net transactions value: -$1,361,598
Form type: 4
Filing time: 13 Apr 2023, 17:14:18 UTC
Previous filing: 03 Apr 2023
Next filing: 18 Apr 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	VKTX	Common Stock, par value $0.00001 per share	Options Exercise	$102,152	+54,336	+2.3%	$1.88^*	2,387,299	13 Apr 2023	Direct	F1
transaction	VKTX	Common Stock, par value $0.00001 per share	Sale	$1,463,749	-79,336	-3.3%	$18.45	2,307,963	13 Apr 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	VKTX	Stock Option (right to buy)	Options Exercise	$0	-54,336	-100%	$0.000000^*	0	13 Apr 2023	Common Stock	54,336	$1.88	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person